ABBN.SW: $86.10 ▼ -2.46 (-2.78%)ASML.AS: $1,560.80 ▼ -95.00 (-5.74%)ENR.DE: $162.50 ▼ -6.64 (-3.93%)GLEN.L: $537.60 ▲ 2.30 (0.43%)IFX.DE: $80.56 ▼ -5.38 (-6.26%)NOKIA.HE: $12.14 ▲ 0.14 (1.13%)RIO.L: $7,280.00 ▲ 16.00 (0.22%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Exact Sciences Corporation

EXAS - NASDAQ

Identifiants & Marche

Ticker EXAS
ISIN US30063P1057
CIK 0001124140
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.